Trial Profile
Multicenter, Randomized, Open-Label Study To Compare The Efficacy, Tolerance And Quality Of Life Of 5 Years Of Adjuvant Exemestane (Aromasin) Therapy With 2.5 To 3 Years Of Adjuvant Tamoxifen Therapy, Followed By 2 To 2.5 Years Of Exemestane For A Total Duration Of 5 Years To Treat HR+ Post-Menopausal Patients With Non-Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jun 2023
Price :
$35
*
At a glance
- Drugs Exemestane (Primary) ; Tamoxifen
- Indications Adenocarcinoma; Early breast cancer
- Focus Therapeutic Use
- Acronyms TEAM
- Sponsors Pfizer
- 06 Jun 2023 Results assessing prognostic performance of Breast Cancer Index and BCIN+ as a continuous risk score for overall and late distant recurrence , presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 18 Jul 2017 10-year long-term follow up results (n=6120) published in the Lancet Oncology
- 12 Dec 2015 Results of subgroup analysis from UK TEAM cohort presented at the 38th Annual San Antonio Breast Cancer Symposium